Rocket Pharmaceuticals Securities Class Action Lawsuit: Important August 11 Deadline for Lead Plaintiff

Purchasers of Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs due to a class action lawsuit. A lead plaintiff must be appointed by August 11, 2025, to direct the litigation. The Rosen Law Firm, a global investor rights law firm, has already filed a lawsuit and encourages investors to select qualified counsel with a track record of success.

Key Takeaways:

• The lawsuit claims that Rocket Pharmaceuticals made false and/or misleading statements about its RP-A501 clinical trial protocol, safety, and clinical, regulatory, and commercial prospects.
• The class period spans September 17, 2024, to May 26, 2025, both dates inclusive.
• The lead plaintiff deadline is August 11, 2025.
• Investors who purchased Rocket Pharmaceuticals securities during the class period may be entitled to compensation.
• The Rosen Law Firm has a history of successful securities class action settlements, including the largest ever securities class action settlement against a Chinese company at the time.
• The firm has recovered hundreds of millions of dollars for investors and has been recognized by law360, Lawdragon, and Super Lawyers.

Statistics:

• The class action lawsuit has already been filed.
• The lead plaintiff deadline is August 11, 2025.
• The lawsuit claims that investors suffered damages due to the defendants' false and/or misleading statements.
• The Rosen Law Firm has secured over $438 million in settlements for investors in 2019 alone.
• The firm has recovered hundreds of millions of dollars for investors since 2013.

Sources:

• GlobeNewswire, "Rosen Law Firm Reminds Purchasers of Rocket Pharmaceuticals, Inc. Securities of Important Lead Plaintiff Deadline" (July 25, 2025)
• The Rosen Law Firm's website and contact information